A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: Results of the Cancer and Leukaemia Group B 90102 Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Transitional Cell
  • Urologic Neoplasms

abstract

  • The combination of cisplatin, fixed dose-rate gemcitabine and gefitinib is active in advanced TCC, although the relative contribution of gefitinib cannot be determined. However, this regimen was associated with excessive toxicity.

publication date

  • January 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1111/j.1464-410X.2007.07226.x

PubMed ID

  • 17922873

Additional Document Info

start page

  • 20

end page

  • 5

volume

  • 101

number

  • 1